French wrestle with major concerns over biosimilar substitution
This article was originally published in SRA
Executive Summary
French industry and government representatives are working to find ways to temper the effects of last December's law permitting biosimilar substitution, although their room for manoeuvre may be limited as the authorities will not want to backtrack and thereby lose face over this potentially cost-saving measure.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.